Reviewer's report

Title: Prevalence and antimicrobial susceptibility of asymptomatic bacteriuria among women with pelvic organ prolapse in Abakaliki, South-East Nigeria.

Version: 0 Date: 18 May 2017

Reviewer: Azubuike Onyebuchi

Reviewer's report:
Please include all comments for the authors in this box rather than uploading your report as an attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting materials or other aspects of your report which cannot be included in a text format.

Please overwrite this text when adding your comments to the authors.

COMMENTS
P2,L24: SPSS rather old; currently IBM SPSS since 2009
P2,L40: Sensitivity pattern was not captured in your conclusion
P3L46: There should be space after superfix 10
P4L2: Organisms should be Organism
There was nothing on susceptibility in your introduction
P4L58: The study is descriptive rather than analytical
P5L5: "on the finding the prevalence": needs to be corrected
P5L7: add as well as bacteriological susceptibility patterns
P5L22: why was the sample size increased to 96
P5L32: How was urine collected to ensure clean catch
P5L32: What type of sterile container was used
P5,L53: Detail of sensitivity card used is needed
P7,L33: Table 2; What is the purpose of the t-test as this finding cannot be used to determine if age is a risk factor.
P7,L43: Table 3; similar to above
P8,L45-59: Tetracycline, Chloramphenicol, Cloxacillin, Streptomycin, Nalidixic acid, Augmentin, Erythromycin, Amoxicillin and Nitrofurantoin were not among the antibiotics used in your methodology; refer to P5,L54-56

P9,L56: Table 5; Proteus is both sensitive and resistant to Nalidixic acid, Gentamycin and Ofloxacin: How?

P10,L1-15: Similar to comment in P8,L45-59 above

P10,L14: What is the basis of comparing patients with POP and pregnant women; They are of different population

P10,L18: This study is not on pregnant women

P10,L20: This study nor the study quoted here did not compare asymptomatic bacteriuria (AB) in pregnant women versus in women with POP

P10,L32: The population for comparism are dissimilar

P10,L40: Explaining the difference in prevalence in males versus females in not necessary for this work as it is not part of this work

P10,L43: Does it mean that VVF is a greater risk factor for AB than POP; This inference cannot be drawn from this study, hence the statement is not necessary

P11,L18: What proportion of women that had AB had organisms that were sensitive to Ciprofloxacin.; What organisms were sensitive to Ciprofloxacin

P11,L10: Most are also sensitive to commonly prescribed antibiotics

Conflict of interest was not declared
Limitation of study was not seen
Recommendations from the study was not available.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have no competing interest
I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal